Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Purinergic Signal. 2022 Dec;18(4):421-433. doi: 10.1007/s11302-022-09880-4. Epub 2022 Jul 11.
Within the family of purinergic receptors, the P2X1 receptor is a ligand-gated ion channel that plays a role in urogenital, immune and cardiovascular function. Specifically, the P2X1 receptor has been implicated in controlling smooth muscle contractions of the vas deferens and therefore has emerged as an exciting drug target for male contraception. In addition, the P2X1 receptor contributes to smooth muscle contractions of the bladder and is a target to treat bladder dysfunction. Finally, platelets and neutrophils have populations of P2X1 receptors that could be targeted for thrombosis and inflammatory conditions. Drugs that specifically target the P2X1 receptor have been challenging to develop, and only recently have small molecule antagonists of the P2X1 receptor been available. However, these ligands need further biological validation for appropriate selectivity and drug-like properties before they will be suitable for use in preclinical models of disease. Although the atomic structure of the P2X1 receptor has yet to be determined, the recent discovery of several other P2X receptor structures and improvements in the field of structural biology suggests that this is now a distinct possibility. Such efforts may significantly improve drug discovery efforts at the P2X1 receptor.
在嘌呤能受体家族中,P2X1 受体是一种配体门控离子通道,在泌尿生殖、免疫和心血管功能中发挥作用。具体来说,P2X1 受体已被牵涉到控制输精管平滑肌收缩,因此它已成为男性避孕的一个令人兴奋的药物靶点。此外,P2X1 受体有助于膀胱平滑肌收缩,是治疗膀胱功能障碍的靶点。最后,血小板和中性粒细胞都有 P2X1 受体群体,可作为血栓形成和炎症状态的靶点。专门针对 P2X1 受体的药物一直难以开发,直到最近才有了 P2X1 受体的小分子拮抗剂。然而,这些配体在适合用于疾病的临床前模型之前,还需要进一步的生物学验证,以确保其具有适当的选择性和类药性。尽管 P2X1 受体的原子结构尚未确定,但最近发现了其他几种 P2X 受体结构,以及结构生物学领域的改进,这表明现在这是一种可能性。这些努力可能会极大地改善 P2X1 受体的药物发现工作。